Takeda Targets Dr. Reddy's Over Generic Dexilant

Law360, New York (April 4, 2011, 3:07 PM EDT) -- Takeda Pharmaceutical Co. Ltd. launched a patent infringement suit Friday in New York over Dr. Reddy’s Laboratories Ltd.’s efforts to manufacture a generic version of acid reflux treatment Dexilant.

The Indian generic-drug maker and its U.S. subsidiary Dr. Reddy’s Laboratories Inc. have infringed U.S. Patent Numbers 6,664,276 and 7,790,755 through the submission of an abbreviated new drug application seeking approval to market their own version of Dexilant, Takeda contends in a complaint filed in the U.S. District Court for the Southern District of New York....
To view the full article, register now.